EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of loading dose β-lactam therapy on outcomes of KPC-producing Klebsiella pneumoniae bloodstream infections in non-ICU patients: a real world study

Luisa Frallonardo, Giacomo Guido iD, Nicolò De Gennaro, Giuseppina De Iaco iD, Fabio Signorile, Marinella Cibelli, Antonio De Luca, Annunziata Ilenia Ritacco, Stefania Stolfa, Francesco Di Gennaro, Annalisa Saracino

Journal of Antimicrobial Chemotherapy · 04.03.2026 · 81 (4)

DOI: 10.1093/jac/dkag087 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 05.03.2026. Verfasst von Luisa Frallonardo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Clinic of Infectious Diseases, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari Aldo Moro, Bari 7012…. Hauptthemen laut MEDLINE: Klebsiella Infections, Klebsiella pneumoniae, Anti-Bacterial Agents, beta-Lactamases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Bloodstream infections (BSIs) caused by KPC-producing Klebsiella pneumoniae (KPC-Kp) remain associated with high mortality, even outside intensive care units (ICUs). Optimizing early β-lactam exposure through a loading dose (LD) of ceftazidime–avibactam or meropenem–vaborbactam may improve outcomes, but evidence in non-ICU settings is limited.

Methods

We conducted a retrospective single-centre study (January 2023–June 2025) including adult non-ICU inpatients with genotypically confirmed KPC-Kp BSI. The control group received standard dosing (ceftazidime–avibactam 2 g/0.5 g q8h or meropenem–vaborbactam 2 g/2 g q8h, both over 3 h). The LD group received either one standard dose infused over 30 min (Scheme A) or one standard dose + 50% infused over 2–3 h (Scheme B), followed by the standard regimen q8h. Primary outcomes were 7- and 30-day all-cause mortality; secondary outcomes included microbiological clearance ≤72 h, ICU transfer and/or vasopressor use, adverse events (AEs ≥ grade 2), hospital stay, and recurrence ≤30 days.

Results

A total of 189 patients were included (140 controls, 49 LD). Groups were comparable in age (median 74 years), comorbidities (Charlson 5), and renal function (eGFR ≈45 mL/min/1.73 m²). LD was associated with faster blood-culture clearance (78% versus 55%; RR 1.26, 95% CI 1.03–1.61, P = 0.02) and lower ICU/vasopressor requirement (7.5% versus 23%; RR 0.60, 95% CI 0.29–0.93, P = 0.02). Median hospital stay was shorter (33 versus 37 days, P = 0.3). Thirty-day mortality was lower in LD (16.3% versus 21.0%; adjusted RR 0.62, 95% CI 0.39–1.29, P = 0.23), indicating a non-significant but clinically relevant trend. No increase in adverse events or nephrotoxicity was observed.

Conclusions

In non-ICU KPC-Kp BSIs, a β-lactam loading dose regimen was associated with faster microbiological clearance, reduced ICU transfer and shorter hospital stay, without added toxicity. Mortality showed a non-significant trend towards improvement. Pragmatic LD strategies may enhance early β-lactam exposure where therapeutic drug monitoring (TDM) is unavailable. Prospective PK/PD-guided studies are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Klebsiella InfectionsKlebsiella pneumoniaeAnti-Bacterial Agentsbeta-Lactamasesbeta-LactamsBacteremiaHumansFemaleRetrospective StudiesMaleAgedMiddle AgedTreatment OutcomeCeftazidimeDrug CombinationsMeropenemAzabicyclo CompoundsAged, 80 and overBoronic AcidsHeterocyclic Compounds, 1-Ring

Substanzen

Anti-Bacterial Agentsbeta-Lactamasesbeta-LactamsCeftazidimeDrug CombinationsMeropenemavibactam, ceftazidime drug combinationAzabicyclo Compoundsmeropenem and vaborbactamBoronic Acids

Autor:innen und Institutionen

  • Clinic of Infectious Diseases, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari Aldo Moro, Bari 70124, Italy.
  • Microbiology and Virology Unit, Department of Interdisciplinary Medicine, University of Bari 'A. Moro', Bari 70124, Italy.

ORCID-Profile: Giacomo Guido, Giuseppina De Iaco

Zitieren

APA

Frallonardo, L., Guido, G., De Gennaro, N., De Iaco, G., Signorile, F., Cibelli, M., De Luca, A., Ritacco, A. I., Stolfa, S., Di Gennaro, F., & Saracino, A. (2026). Impact of loading dose β-lactam therapy on outcomes of KPC-producing Klebsiella pneumoniae bloodstream infections in non-ICU patients: a real world study. Journal of Antimicrobial Chemotherapy, 81(4). https://doi.org/10.1093/jac/dkag087

Vancouver

Frallonardo L, Guido G, De Gennaro N, De Iaco G, Signorile F, Cibelli M, et al. Impact of loading dose β-lactam therapy on outcomes of KPC-producing Klebsiella pneumoniae bloodstream infections in non-ICU patients: a real world study. Journal of Antimicrobial Chemotherapy. 2026;81(4). doi:10.1093/jac/dkag087

BibTeX
@article{Frallonardo2026,
  author = {Frallonardo, Luisa and Guido, Giacomo and De Gennaro, Nicolò and De Iaco, Giuseppina and Signorile, Fabio and Cibelli, Marinella and De Luca, Antonio and Ritacco, Annunziata Ilenia and Stolfa, Stefania and Di Gennaro, Francesco and Saracino, Annalisa},
  title = {Impact of loading dose β-lactam therapy on outcomes of KPC-producing Klebsiella pneumoniae bloodstream infections in non-ICU patients: a real world study},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  volume = {81},
  number = {4},
  doi = {10.1093/jac/dkag087}
}
Kostenlos starten →